Robertson Stephens Wealth Management LLC Reduces Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Robertson Stephens Wealth Management LLC lessened its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 6.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 172,186 shares of the company’s stock after selling 11,500 shares during the quarter. Robertson Stephens Wealth Management LLC’s holdings in Adaptive Biotechnologies were worth $1,032,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Impact Partnership Wealth LLC grew its holdings in shares of Adaptive Biotechnologies by 8.8% during the fourth quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,539 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Adaptive Biotechnologies by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company’s stock worth $177,000 after purchasing an additional 2,710 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Adaptive Biotechnologies by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company’s stock worth $188,000 after purchasing an additional 2,928 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Adaptive Biotechnologies by 30.8% during the third quarter. Vontobel Holding Ltd. now owns 17,000 shares of the company’s stock worth $87,000 after purchasing an additional 4,000 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Adaptive Biotechnologies by 11.7% during the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company’s stock worth $275,000 after buying an additional 4,799 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Down 0.5 %

Shares of NASDAQ:ADPT opened at $8.01 on Friday. The company has a market cap of $1.18 billion, a P/E ratio of -5.98 and a beta of 1.50. Adaptive Biotechnologies Co. has a 52 week low of $2.28 and a 52 week high of $8.33. The company has a 50-day moving average price of $6.76 and a 200 day moving average price of $5.47.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ADPT shares. The Goldman Sachs Group increased their target price on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Piper Sandler increased their target price on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, BTIG Research increased their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.